These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 17971772

  • 1. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer.
    Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY, Stanimirovic A, Encioiu E, Neill M, Loblaw DA, Trachtenberg J, Narod SA, Seth A.
    Br J Cancer; 2007 Dec 17; 97(12):1690-5. PubMed ID: 17971772
    [Abstract] [Full Text] [Related]

  • 2. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
    Kulda V, Topolcan O, Kucera R, Kripnerova M, Srbecka K, Hora M, Hes O, Klecka J, Babuska V, Rousarova M, Benson V, Pesta M.
    Anticancer Res; 2016 Sep 17; 36(9):4787-93. PubMed ID: 27630329
    [Abstract] [Full Text] [Related]

  • 3. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression.
    Nam RK, Sugar L, Wang Z, Yang W, Kitching R, Klotz LH, Venkateswaran V, Narod SA, Seth A.
    Cancer Biol Ther; 2007 Jan 17; 6(1):40-5. PubMed ID: 17172822
    [Abstract] [Full Text] [Related]

  • 4. Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: preliminary results.
    Bonaccorsi L, Nesi G, Nuti F, Paglierani M, Krausz C, Masieri L, Serni S, Proietti-Pannunzi L, Fang Y, Jhanwar SC, Orlando C, Carini M, Forti G, Baldi E, Luzzatto L.
    J Endocrinol Invest; 2009 Jul 17; 32(7):590-6. PubMed ID: 19494719
    [Abstract] [Full Text] [Related]

  • 5. Prostate cancer genes associated with TMPRSS2-ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts.
    Barwick BG, Abramovitz M, Kodani M, Moreno CS, Nam R, Tang W, Bouzyk M, Seth A, Leyland-Jones B.
    Br J Cancer; 2010 Feb 02; 102(3):570-6. PubMed ID: 20068566
    [Abstract] [Full Text] [Related]

  • 6. Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers.
    Möller K, Wecker AL, Höflmayer D, Fraune C, Makrypidi-Fraune G, Hube-Magg C, Kluth M, Steurer S, Clauditz TS, Wilczak W, Simon R, Sauter G, Huland H, Heinzer H, Haese A, Schlomm T, Weidemann S, Luebke AM, Minner S, Bernreuther C, Bonk S, Marx A.
    Virchows Arch; 2020 Nov 02; 477(5):625-636. PubMed ID: 32417965
    [Abstract] [Full Text] [Related]

  • 7. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.
    Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA.
    Mod Pathol; 2008 Feb 02; 21(2):67-75. PubMed ID: 18065961
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Detection of TMPRSS2-ERG Fusion Transcript in Biopsy Specimen of Prostate Cancer Patients: A Single Centre Experience.
    Trifunovski A, Dimovski A, Dohcev S, Stavridis S, Stankov O, Saidi S, Gjorgjievska M, Popov Z.
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Jun 01; 41(1):5-14. PubMed ID: 32573479
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair.
    Dal Pra A, Lalonde E, Sykes J, Warde F, Ishkanian A, Meng A, Maloff C, Srigley J, Joshua AM, Petrovics G, van der Kwast T, Evans A, Milosevic M, Saad F, Collins C, Squire J, Lam W, Bismar TA, Boutros PC, Bristow RG.
    Clin Cancer Res; 2013 Sep 15; 19(18):5202-9. PubMed ID: 23918607
    [Abstract] [Full Text] [Related]

  • 12. Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.
    Grupp K, Roettger L, Kluth M, Hube-Magg C, Simon R, Lebok P, Minner S, Tsourlakis MC, Koop C, Graefen M, Adam M, Haese A, Wittmer C, Sauter G, Wilczak W, Huland H, Schlomm T, Steurer S, Krech T.
    Oncol Rep; 2015 Sep 15; 34(3):1211-20. PubMed ID: 26134445
    [Abstract] [Full Text] [Related]

  • 13. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
    Sabaliauskaite R, Jarmalaite S, Petroska D, Dasevicius D, Laurinavicius A, Jankevicius F, Lazutka JR.
    Genes Chromosomes Cancer; 2012 Aug 15; 51(8):781-91. PubMed ID: 22505341
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
    Xiao L, Zhu XZ, Wang Y, Gong Y, Guo CC.
    Zhonghua Bing Li Xue Za Zhi; 2011 Jun 15; 40(6):392-6. PubMed ID: 21914348
    [Abstract] [Full Text] [Related]

  • 16. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
    Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG.
    Urol Oncol; 2013 Jul 15; 31(5):566-71. PubMed ID: 21600800
    [Abstract] [Full Text] [Related]

  • 17. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.
    Saramäki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T.
    Clin Cancer Res; 2008 Jun 01; 14(11):3395-400. PubMed ID: 18519769
    [Abstract] [Full Text] [Related]

  • 18. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy.
    Grupp K, Höhne TS, Prien K, Hube-Magg C, Tsourlakis MC, Sirma H, Pham T, Heinzer H, Graefen M, Michl U, Simon R, Wilczak W, Izbicki J, Sauter G, Minner S, Schlomm T, Steurer S.
    Exp Mol Pathol; 2013 Oct 01; 95(2):227-34. PubMed ID: 23948277
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.